title: Antiprogestins and iatrogenic glucocorticoid resistance.
abstract: The antiglucocorticoid action of the antiprogestin RU 38486 has interfered with its successful clinical application in long-term treatment. Several new antiprogestins (Org 31710, Org 31806 and ZK 98299) have recently been developed with the aim to eliminate this side-effect. We have used a human lymphocyte proliferation assay to estimate the antiglucocorticoid potency of RU 38486 and the newer antiprogestins. In this assay 100 nmol/L RU 38486 shifted the dexamethasone inhibition curve by at least one order of magnitude. The other antiprogestins showed no effect at 100 nmol/L. RU 38486 (30 nmol/L) was able to antagonize 1000 nmol/L dexamethasone. The other antiprogestins showed only slight effects even at 1000 nmol/L. We conclude that the new antiprogestins have antiglucocorticoid effects that are one to two orders of magnitude lower than that of RU 38486. This may make them more suitable than RU 38486 for application in long-term antiprogestin treatment.
authors.affiliation: Department of Internal Medicine III, Erasmus University Rotterdam, The Netherlands. koper@inw3.fgg.eur.nl
authors.forename: J W
authors.initials: JW
authors.lastname: Koper
authors.forename: G J
authors.initials: GJ
authors.lastname: Molijn
authors.forename: C J
authors.initials: CJ
authors.lastname: van Uffelen
authors.forename: E
authors.initials: E
authors.lastname: Stigter
authors.forename: S W
authors.initials: SW
authors.lastname: Lamberts
mesh_terms: D001667:Binding, Competitive; D003907:Dexamethasone / Q000037:antagonists & inhibitors; D004351:Drug Resistance; D004963:Estrenes / Q000009:adverse effects / Q000378:metabolism / Q000494:pharmacology; D005663:Furans / Q000009:adverse effects / Q000378:metabolism / Q000494:pharmacology; D005938:Glucocorticoids / Q000037:antagonists & inhibitors*; D006067:Gonanes / Q000009:adverse effects / Q000378:metabolism / Q000494:pharmacology; D006727:Hormone Antagonists / Q000009:adverse effects* / Q000378:metabolism / Q000494:pharmacology*; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D066298:In Vitro Techniques; D008213:Lymphocyte Activation / Q000187:drug effects; D008577:Meningeal Neoplasms / Q000188:drug therapy / Q000378:metabolism; D008579:Meningioma / Q000188:drug therapy / Q000378:metabolism; D015735:Mifepristone / Q000009:adverse effects* / Q000378:metabolism / Q000494:pharmacology*; D011372:Progestins / Q000037:antagonists & inhibitors*; D011965:Receptors, Glucocorticoid / Q000187:drug effects / Q000378:metabolism
chemical_list: D004963:Estrenes; D005663:Furans; D005938:Glucocorticoids; D006067:Gonanes; D006727:Hormone Antagonists; D011372:Progestins; D011965:Receptors, Glucocorticoid; C076196:Org 31710; C076197:Org 31806; D015735:Mifepristone; D003907:Dexamethasone; C053238:onapristone; D006854:Hydrocortisone